Article

Avastin for Refractory Glioblastoma and Oxaliplatin for Colon Cancer

As presented at ASCO, second-line bevacizumab (Avastin) as monotherapy has been associated with a 28% response rate and an overall survival edge for refractory glioblastoma. Also presented at the ASCO meeting, adding oxaliplatin (Eloxatin) to a standard chemotherapy regimen for stage II or III colon cancer may provide a small five-year survival advantage.

Related Videos
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Andreas Kremer, MD, PhD, MHBA | Credit: AASLD
Jörn Schattenberg, MD | Credit: Novo Nordisk
Diabetes Dialogue: Diabetes Tech Updates from November 2024 | Image Credit: HCPLive
Related Content
David J. Kuter, MD, DPhil, program director of hematology at Massachusetts General Hospital and professor of medicine at Harvard Medical School in Boston
December 7th 2024

Rilzabrutinib Improves Platelet Response, Quality of Life in Immune Thrombocytopenia Compared to Placebo

Victoria Johnson
Patient Education Tips for CSU and Final Thoughts
November 29th 2024

Patient Education Tips for CSU and Final Thoughts

David Khan, MD Kristin Sokol, MD Vivian Hernandez-Trujillo, MD Priya Bansal, MD
No Link Found Between Allergic Reaction Severity and Allergen Amount
December 6th 2024

No Link Found Between Allergic Reaction Severity and Allergen Amount

Tim Smith
Medical Ethics Unpacked: Ethical Considerations for Euthanasia and Medically-Assisted Suicide
November 22nd 2024

Medical Ethics Unpacked: Ethical Considerations for Euthanasia & Medical Assistance in Dying

Steven Levine, MD Dominic Sisti, PhD
HCPLive Biosimilar Month in Review
December 6th 2024

Biosimilars Month in Review: November 2024

Victoria Johnson
Iptacopan Boosts Hemoglobin Levels in Adults with PNH in Phase 3b Trial | Image Credit: Aplastic Anemia and MDS International Foundation
December 6th 2024

Iptacopan Boosts Hemoglobin Levels in Adults with PNH in Phase 3b Trial

Connor Iapoce
© 2024 MJH Life Sciences

All rights reserved.